These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 975177)

  • 21. [Effect of pyridinolcarbamate on blood coagulation and thrombolysis in patients with arteriosclerosis obliterans].
    Hess H; Goossens N; Keil-Kuri E; Zollner R; Meyer A
    Vasa; 1972; 1(3):206-11. PubMed ID: 5076123
    [No Abstract]   [Full Text] [Related]  

  • 22. Pyridinolcarbamate, bradykinin antagonist, in patients suffering from arteriosclerosis obliterans and thromboangiitis obliterans (Buerger's disease); a preliminary report on the treatment of human atherosclerosis.
    Shimamoto T; Atsumi T
    Jpn Heart J; 1965 Sep; 6(5):407-15. PubMed ID: 5294603
    [No Abstract]   [Full Text] [Related]  

  • 23. The effect of Prodectin (pyridinolcarbamate) treatment of the circulation rate in obliterating arterial diseases of the lower extremities.
    Fényes G; Gótzy G; Fehrentheil L
    Ther Hung; 1975; 23(2):64-66. PubMed ID: 1188705
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment of atherosclerosis obliterans with pyridinolcarbamate.
    Atsumi T; Motomiya T; Isokane N; Shimamoto T
    Jpn Heart J; 1971 Jul; 12(4):335-46. PubMed ID: 5314713
    [No Abstract]   [Full Text] [Related]  

  • 25. [Prodectin treatment of partial hearing loss as a result of atherosclerosis].
    Smirnova NA; Timakov VA; Mikushkin MK
    Vestn Otorinolaringol; 1982; (6):53-6. PubMed ID: 7179649
    [No Abstract]   [Full Text] [Related]  

  • 26. [Pyridinolcarbamate treatment of ischemic heart disease].
    Kuz'ko NV
    Vrach Delo; 1976 Jan; (1):27-30. PubMed ID: 1246850
    [No Abstract]   [Full Text] [Related]  

  • 27. The use of prodectin in the treatment of cerebral arteriosclerosis and its complications.
    Abrányi I; Máté
    Ther Hung; 1976; 24(1):20-3. PubMed ID: 790631
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical and laboratory examinations with Prodectin.
    Bédi J; Kosztovics A; Pálos LA
    Ther Hung; 1976; 24(3):91-7. PubMed ID: 1013926
    [No Abstract]   [Full Text] [Related]  

  • 29. [Changes of the electrophoretic tracing of the serum glycoproteins in diabetic subjects treated with pyridinolcarbamate].
    Notarbartolo A; Rini GB; Di Fede G
    Boll Soc Ital Cardiol; 1973; 18(4):379-83. PubMed ID: 4807078
    [No Abstract]   [Full Text] [Related]  

  • 30. [Clinical tests using pyridinol carbamate on the arterial circulation and blood coagulation in patients with arteriosclerosis obliterans].
    De Soldati L; Castro CM; Grilli H; Reussi J
    Prensa Med Argent; 1969 May; 56(12):546-53. PubMed ID: 5343928
    [No Abstract]   [Full Text] [Related]  

  • 31. [Evaluation of the effectiveness of anginine treatment of diabetic microangiopathies].
    Spesivtseva VG; Frenkel' VKh; Mamaeva GG; Sokolovskiĭ GA; Kukes VG
    Sov Med; 1975 Jul; (7):42-5. PubMed ID: 1216049
    [No Abstract]   [Full Text] [Related]  

  • 32. [Effect of complamin and prodectin on microcirculation and lipid metabolism in psoriasis patients].
    Rakhmatov AB; Bilash NV
    Vestn Dermatol Venerol; 1983 Apr; (4):15-8. PubMed ID: 6868813
    [No Abstract]   [Full Text] [Related]  

  • 33. [Activity of the kallikrein-kinin system in patients with ischemic heart disease treated with parmidine].
    Vygovskiĭ VP; Zaremba EF; Podil'chak EM; Dutka RIa; Gorgota OV
    Vrach Delo; 1985 Sep; (9):6-8. PubMed ID: 2416131
    [No Abstract]   [Full Text] [Related]  

  • 34. A multiclinic double-blind trial of pyridinolcarbamate and inositol niacinate in ischemic ulcer due to chronic arterial occlusion.
    Mishima Y; Kamiya K; Sakaguchi S; Kusaba A; Sakuma A
    Angiology; 1977 Feb; 28(2):84-94. PubMed ID: 326097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Attempts to delay progression in occlusive atherosclerosis.
    Terry EN; Rouen LR; Clasuss RH; Katz MC; Redisch W
    Ann N Y Acad Sci; 1976; 275():379-85. PubMed ID: 1070279
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical pharmacologic evaluation of the antiatherosclerotic agent, pyridinolcarbamate. A double-blind crossover trial in the treatment of atherosclerosis obliterans.
    Shimamoto T; Atsumi T; Yamashita S; Motomiya T; Isokane N; Ishioka T; Sakuma A
    Am Heart J; 1970 Jan; 79(1):5-19. PubMed ID: 4903137
    [No Abstract]   [Full Text] [Related]  

  • 37. [A double blind crossover trial in pyridinolcarbamate treatment of atherosclerosis obliterans].
    Yamashita S
    Nihon Naika Gakkai Zasshi; 1969 Apr; 58(4):283-92. PubMed ID: 4896659
    [No Abstract]   [Full Text] [Related]  

  • 38. [Treatment of arteriosclerosis obliterans with pyridinolcarbamate].
    Atsumi T; Isokane N; Yamashita S; Sano T; Odakura T; Kurai A
    Nihon Naika Gakkai Zasshi; 1967 Sep; 56(9):983-92. PubMed ID: 5627161
    [No Abstract]   [Full Text] [Related]  

  • 39. [Biopharmaceutical studies on pyridinolcarbamate. I. Effect of continuous pyridinolcarbamate administration on renal excretion of sulfonamides in rabbits (author's transl)].
    Ichibagase H; Imamura Y; Suenaga A; Kawabata H
    Yakugaku Zasshi; 1978 Nov; 98(10):1398-402. PubMed ID: 745048
    [No Abstract]   [Full Text] [Related]  

  • 40. [Comparison of the effectiveness of anginin and stugeron treatment of cerebral arteriosclerosis].
    Sobczyk W; Kruszewska J; Szymchel J
    Neurol Neurochir Pol; 1980; 14(2):183-9. PubMed ID: 6993976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.